China Expands Drug-Buying Program to Cut Costs for Patients
- New list includes 33 drugs for dementia, diabetes, infections
- More than four firms to be chosen in national procurement plan
This article is for subscribers only.
China is expanding its generic drug-procurement program to include an additional 33 drugs, pitting domestic and international drugmakers in a price war that could see Chinese players dominate.
Less than three months after China went nationwide with a pilot bulk-buying program for 25 medicines, the government on Sunday announced a second batch of 33 drugs treating everything from diabetes and infections to dementia.